ngm621

NGM621 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to potently inhibit complement component 3 (C3), a central protein in the complement cascade. It is administered via intravitreal injection and has been developed primarily for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). By inhibiting C3, NGM621 aims to broadly suppress downstream effector functions of the complement system, including inflammation and cell lysis, which are implicated in GA progression. The drug was discovered by NGM Biopharmaceuticals under a collaboration with Merck and has received Fast Track designation from the FDA for this indication. Clinical trials have shown that it is well tolerated but did not reach statistical significance in reducing GA lesion growth compared to sham treatment[1][2][5][7].

Other names

NGM 621NGM621NGM-621